List of Tables
Table 1. Global Antifibrotic Drug Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antifibrotic Drug Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antifibrotic Drug Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antifibrotic Drug Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antifibrotic Drug Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antifibrotic Drug Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antifibrotic Drug Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antifibrotic Drug Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antifibrotic Drug, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antifibrotic Drug, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antifibrotic Drug, Product Types and Applications
Table 12. Global Key Manufacturers of Antifibrotic Drug, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antifibrotic Drug Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antifibrotic Drug Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antifibrotic Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antifibrotic Drug Sales by Region (K Units), 2021–2026
Table 18. Global Antifibrotic Drug Sales Market Share by Region (2021–2026)
Table 19. Global Antifibrotic Drug Sales by Region (K Units), 2027–2032
Table 20. Global Antifibrotic Drug Sales Market Share by Region (2027–2032)
Table 21. Global Antifibrotic Drug Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antifibrotic Drug Revenue Market Share by Region (2021–2026)
Table 23. Global Antifibrotic Drug Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antifibrotic Drug Revenue Market Share by Region (2027–2032)
Table 25. North America Antifibrotic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antifibrotic Drug Sales by Country (K Units), 2021–2026
Table 27. North America Antifibrotic Drug Sales by Country (K Units), 2027–2032
Table 28. North America Antifibrotic Drug Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antifibrotic Drug Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antifibrotic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antifibrotic Drug Sales by Country (K Units), 2021–2026
Table 32. Europe Antifibrotic Drug Sales by Country (K Units), 2027–2032
Table 33. Europe Antifibrotic Drug Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antifibrotic Drug Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antifibrotic Drug Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antifibrotic Drug Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antifibrotic Drug Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antifibrotic Drug Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antifibrotic Drug Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antifibrotic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antifibrotic Drug Sales by Country (K Units), 2021–2026
Table 42. Latin America Antifibrotic Drug Sales by Country (K Units), 2027–2032
Table 43. Latin America Antifibrotic Drug Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antifibrotic Drug Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antifibrotic Drug Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antifibrotic Drug Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antifibrotic Drug Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antifibrotic Drug Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antifibrotic Drug Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antifibrotic Drug Sales (K Units) by Type (2021–2026)
Table 51. Global Antifibrotic Drug Sales (K Units) by Type (2027–2032)
Table 52. Global Antifibrotic Drug Sales Market Share by Type (2021–2026)
Table 53. Global Antifibrotic Drug Sales Market Share by Type (2027–2032)
Table 54. Global Antifibrotic Drug Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antifibrotic Drug Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antifibrotic Drug Revenue Market Share by Type (2021–2026)
Table 57. Global Antifibrotic Drug Revenue Market Share by Type (2027–2032)
Table 58. Global Antifibrotic Drug Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antifibrotic Drug Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antifibrotic Drug Sales (K Units) by Application (2021–2026)
Table 61. Global Antifibrotic Drug Sales (K Units) by Application (2027–2032)
Table 62. Global Antifibrotic Drug Sales Market Share by Application (2021–2026)
Table 63. Global Antifibrotic Drug Sales Market Share by Application (2027–2032)
Table 64. Global Antifibrotic Drug Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antifibrotic Drug Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antifibrotic Drug Revenue Market Share by Application (2021–2026)
Table 67. Global Antifibrotic Drug Revenue Market Share by Application (2027–2032)
Table 68. Global Antifibrotic Drug Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antifibrotic Drug Price (US$/Unit) by Application (2027–2032)
Table 70. Boehringer Ingelheim Company Information
Table 71. Boehringer Ingelheim Description and Business Overview
Table 72. Boehringer Ingelheim Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Boehringer Ingelheim Antifibrotic Drug Product
Table 74. Boehringer Ingelheim Recent Developments/Updates
Table 75. Roche Company Information
Table 76. Roche Description and Business Overview
Table 77. Roche Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Roche Antifibrotic Drug Product
Table 79. Roche Recent Developments/Updates
Table 80. Accord Healthcare Company Information
Table 81. Accord Healthcare Description and Business Overview
Table 82. Accord Healthcare Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Accord Healthcare Antifibrotic Drug Product
Table 84. Accord Healthcare Recent Developments/Updates
Table 85. Amneal Pharmaceuticals Company Information
Table 86. Amneal Pharmaceuticals Description and Business Overview
Table 87. Amneal Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Amneal Pharmaceuticals Antifibrotic Drug Product
Table 89. Amneal Pharmaceuticals Recent Developments/Updates
Table 90. Sandoz Company Information
Table 91. Sandoz Description and Business Overview
Table 92. Sandoz Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Sandoz Antifibrotic Drug Product
Table 94. Sandoz Recent Developments/Updates
Table 95. Teva Company Information
Table 96. Teva Description and Business Overview
Table 97. Teva Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Teva Antifibrotic Drug Product
Table 99. Teva Recent Developments/Updates
Table 100. ScieGen Pharmaceuticals Company Information
Table 101. ScieGen Pharmaceuticals Description and Business Overview
Table 102. ScieGen Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. ScieGen Pharmaceuticals Antifibrotic Drug Product
Table 104. ScieGen Pharmaceuticals Recent Developments/Updates
Table 105. Apotex Company Information
Table 106. Apotex Description and Business Overview
Table 107. Apotex Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Apotex Antifibrotic Drug Product
Table 109. Apotex Recent Developments/Updates
Table 110. Gyre Pharmaceuticals Company Information
Table 111. Gyre Pharmaceuticals Description and Business Overview
Table 112. Gyre Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Gyre Pharmaceuticals Antifibrotic Drug Product
Table 114. Gyre Pharmaceuticals Recent Developments/Updates
Table 115. Kawin Company Information
Table 116. Kawin Description and Business Overview
Table 117. Kawin Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Kawin Antifibrotic Drug Product
Table 119. Kawin Recent Developments/Updates
Table 120. Beacon Pharma Company Information
Table 121. Beacon Pharma Description and Business Overview
Table 122. Beacon Pharma Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Beacon Pharma Antifibrotic Drug Product
Table 124. Beacon Pharma Recent Developments/Updates
Table 125. Eskayef Pharmaceuticals Company Information
Table 126. Eskayef Pharmaceuticals Description and Business Overview
Table 127. Eskayef Pharmaceuticals Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Eskayef Pharmaceuticals Antifibrotic Drug Product
Table 129. Eskayef Pharmaceuticals Recent Developments/Updates
Table 130. CSPC Pharmaceutical Group Company Information
Table 131. CSPC Pharmaceutical Group Description and Business Overview
Table 132. CSPC Pharmaceutical Group Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. CSPC Pharmaceutical Group Antifibrotic Drug Product
Table 134. CSPC Pharmaceutical Group Recent Developments/Updates
Table 135. Qilu Pharmaceutical Company Information
Table 136. Qilu Pharmaceutical Description and Business Overview
Table 137. Qilu Pharmaceutical Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Qilu Pharmaceutical Antifibrotic Drug Product
Table 139. Qilu Pharmaceutical Recent Developments/Updates
Table 140. Kelun Pharmaceutical Company Information
Table 141. Kelun Pharmaceutical Description and Business Overview
Table 142. Kelun Pharmaceutical Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Kelun Pharmaceutical Antifibrotic Drug Product
Table 144. Kelun Pharmaceutical Recent Developments/Updates
Table 145. PuraCap Company Information
Table 146. PuraCap Description and Business Overview
Table 147. PuraCap Antifibrotic Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. PuraCap Antifibrotic Drug Product
Table 149. PuraCap Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Antifibrotic Drug Distributors List
Table 153. Antifibrotic Drug Customers List
Table 154. Antifibrotic Drug Market Trends
Table 155. Antifibrotic Drug Market Drivers
Table 156. Antifibrotic Drug Market Challenges
Table 157. Antifibrotic Drug Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antifibrotic Drug
Figure 2. Global Antifibrotic Drug Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antifibrotic Drug Market Share by Type: 2025 & 2032
Figure 4. Nintedanib Product Picture
Figure 5. Pirfenidone Product Picture
Figure 6. Global Antifibrotic Drug Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Antifibrotic Drug Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Antifibrotic Drug Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Antifibrotic Drug Market Size (US$ Million), 2021–2032
Figure 13. Global Antifibrotic Drug Sales (K Units), 2021–2032
Figure 14. Global Antifibrotic Drug Average Price (US$/Unit), 2021–2032
Figure 15. Antifibrotic Drug Report Years Considered
Figure 16. Antifibrotic Drug Sales Share by Manufacturers in 2025
Figure 17. Global Antifibrotic Drug Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Antifibrotic Drug Players: Market Share by Revenue in Antifibrotic Drug in 2025
Figure 19. Antifibrotic Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Antifibrotic Drug Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Antifibrotic Drug Sales Market Share by Country (2021–2032)
Figure 22. North America Antifibrotic Drug Revenue Market Share by Country (2021–2032)
Figure 23. United States Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Antifibrotic Drug Sales Market Share by Country (2021–2032)
Figure 26. Europe Antifibrotic Drug Revenue Market Share by Country (2021–2032)
Figure 27. Germany Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Antifibrotic Drug Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Antifibrotic Drug Revenue Market Share by Region (2021–2032)
Figure 34. China Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Antifibrotic Drug Sales Market Share by Country (2021–2032)
Figure 42. Latin America Antifibrotic Drug Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Antifibrotic Drug Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Antifibrotic Drug Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Antifibrotic Drug Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Antifibrotic Drug by Type (2021–2032)
Figure 53. Global Revenue Market Share of Antifibrotic Drug by Type (2021–2032)
Figure 54. Global Antifibrotic Drug Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Antifibrotic Drug by Application (2021–2032)
Figure 56. Global Revenue Market Share of Antifibrotic Drug by Application (2021–2032)
Figure 57. Global Antifibrotic Drug Price (US$/Unit) by Application (2021–2032)
Figure 58. Antifibrotic Drug Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
